Compounds > metformin

metformin and cb-839

metformin has been researched along with cb-839 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alt, J; Chen, B; Elgogary, A; Fu, J; Hanes, J; Hartung, T; Le, A; Lee, R; Liu, Y; Neisser, M; Nguyen, C; Park, JK; Poore, B; Rais, R; Reyes, J; Rojas, C; Semenza, GL; Slusher, BS; Tsukamoto, T; Xia, S; Xu, Q; Zhao, L; Zimmermann, SC1
Addie, RD; Bovée, JVMG; Cleton-Jansen, AM; Cleven, AHG; de Jong, Y; Kruisselbrink, AB; Molenaar, RJ; Niessen, B; Peterse, EFP; van den Akker, BEWM1
Bass, AJ; Beeson, CC; Beeson, GC; Diehl, JA; Ogretmen, B; Oleinik, N; Parnham, S; Qie, S; Rustgi, AK; Wong, KK; Yoshida, A1

Other Studies

3 other study(ies) available for metformin and cb-839

ArticleYear
Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 2016, 09-06, Volume: 113, Issue:36

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Cell Line, Tumor; Glutaminase; Glutamine; Humans; Metformin; Mice; Nanoparticles; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Sulfides; Thiadiazoles; Xenograft Model Antitumor Assays

2016
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
    British journal of cancer, 2018, Volume: 118, Issue:8

    Topics: Antineoplastic Agents; Benzeneacetamides; Bone Neoplasms; Chloroquine; Chondrosarcoma; Drug Screening Assays, Antitumor; Glutaminase; Glutamine; Humans; Immunohistochemistry; Isocitrate Dehydrogenase; Metabolic Networks and Pathways; Metformin; Molecular Targeted Therapy; Mutation; Neoplasm Grading; Thiadiazoles; Tumor Cells, Cultured

2018
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
    Nature communications, 2019, 03-21, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzeneacetamides; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Drug Synergism; Energy Metabolism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; F-Box Proteins; Gene Expression Regulation, Neoplastic; Glutaminase; Glutamine; Humans; Hypoglycemic Agents; Male; Mechanistic Target of Rapamycin Complex 1; Metformin; Mice; Molecular Targeted Therapy; Phenformin; Protein Kinase Inhibitors; Retinoblastoma Protein; Signal Transduction; Thiadiazoles; Xenograft Model Antitumor Assays

2019